Keyword: Aurobindo Pharma
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
Regulatory problems are piling up for the sterile manufacturing operations of India’s Aurobindo, which has had another plant cited by the FDA.
Sanofi, aiming to sharpen its focus by offloading its EU generics, is reportedly drawing shoppers from across the globe. The deal could be worth $2B.
Japan’s JSR bought Crown Biosciences, Aurobindo and Dr. Reddy’s responded to Orchid Pharma report, Tessa raised $80 million.
Aurobindo and Dr. Reddy’s each responded to a report by the Economic Times that said both were front-runners to buy bankrupt Orchid Pharma.
Price-fixing allegations against generics makers just keep piling up, with Mylan, Teva and other players targeted in yet another lawsuit.
Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer.
Eli Lilly’s $500 million-plus ADHD med Strattera succumbed to generics Tuesday as four drugmakers won FDA green lights for their copycat.